Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS

Capricorn Fund Managers Ltd bought a new stake in shares of Glaukos Corporation (NYSE:GKOS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 60,000 shares of the medical instruments supplier’s stock, valued at approximately $6,775,000. Glaukos accounts for approximately 1.6% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 23rd biggest position. Capricorn Fund Managers Ltd owned about 0.10% of Glaukos at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. AustralianSuper Pty Ltd increased its stake in Glaukos by 10.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock worth $36,685,000 after acquiring an additional 43,750 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after acquiring an additional 27,646 shares during the last quarter. Riverbridge Partners LLC grew its holdings in shares of Glaukos by 41.0% in the third quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after purchasing an additional 165,673 shares in the last quarter. Holocene Advisors LP increased its position in Glaukos by 40.1% in the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock worth $108,030,000 after purchasing an additional 299,118 shares during the last quarter. Finally, TD Asset Management Inc bought a new stake in Glaukos in the third quarter worth $1,157,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Price Performance

GKOS opened at $112.68 on Monday. The business has a fifty day moving average of $111.67 and a 200 day moving average of $103.02. The stock has a market cap of $6.54 billion, a P/E ratio of -34.57 and a beta of 0.78. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $130.23.

Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm’s revenue for the quarter was up 35.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) earnings per share. As a group, sell-side analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the subject of several research reports. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Piper Sandler restated an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a report on Wednesday, January 14th. Stifel Nicolaus upped their target price on shares of Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Truist Financial increased their price target on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Wells Fargo & Company boosted their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $133.69.

Insiders Place Their Bets

In other news, CFO Alex R. Thurman sold 2,511 shares of Glaukos stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total transaction of $267,321.06. Following the completion of the sale, the chief financial officer owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. The trade was a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Marc Stapley sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the sale, the director owned 37,449 shares of the company’s stock, valued at $4,782,611.79. The trade was a 28.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 324,657 shares of company stock worth $37,692,269. 5.80% of the stock is owned by company insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.